Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio in Juvenile Idiopathic Arthritis
NCT06024486 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2023-10-06
Summary
The fibrinogen to albumin ratio (FAR) and C-reactive protein to albumin ratio (CAR) have emerged as useful biomarkers to predict systemic inflammation. The aim here is to investigate the relation between FAR/CAR and Juvenile arthritis disease activity score (JASDAS27) in Juvenile idiopathic arthritis (JIA)
Conditions
- Juvenile Idiopathic Arthritis
Interventions
- DIAGNOSTIC_TEST
-
fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)
measurement of serum albumin, fibrinogen and CRP
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Max Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-11-01
- Primary Completion
- 2024-05-01
- Completion
- 2024-07-01
More Related Trials
-
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
NCT05545098 ·Status: UNKNOWN
-
Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years
NCT02894047 ·Status: COMPLETED
-
Serum Interleukin - 17A in Juvenile Idiopathic Arthritis
NCT05688358 ·Status: UNKNOWN
-
Study During Pregnancy of Expression of miRNAs in RA or SLE
NCT02350491 ·Status: COMPLETED
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03414502 ·Status: RECRUITING ·Phase: PHASE3
-
Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis
NCT04201886 ·Status: UNKNOWN ·Phase: PHASE4
-
To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS
NCT02311842 ·Status: COMPLETED
-
Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
NCT01557322 ·Status: COMPLETED
-
A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA
NCT01078597 ·Status: COMPLETED
-
Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents
NCT01691014 ·Status: TERMINATED
-
Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset
NCT00512239 ·Status: RECRUITING
-
Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients
NCT04679272 ·Status: COMPLETED
-
Survivin as Predictive Biomarker for RA
NCT03444623 ·Status: UNKNOWN
-
Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)
NCT00328068 ·Status: UNKNOWN
-
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis
NCT04343378 ·Status: COMPLETED
-
Study of Tapering and Discontinuing Biological DMARDs in Rheumatoid Arthritis Patients
NCT04472390 ·Status: UNKNOWN
-
A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood
NCT00781469 ·Status: TERMINATED
-
Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis
NCT01111357 ·Status: COMPLETED
-
"Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease"
NCT07173582 ·Status: NOT_YET_RECRUITING
-
Prediction of Erosive Disease in Early Rheumatoid Arthritis (RA) by Ultrasound and Cartilage Biodegradation Markers
NCT02464384 ·Status: UNKNOWN ·Phase: NA
-
The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis
NCT00001375 ·Status: COMPLETED
-
Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)
NCT02219347 ·Status: COMPLETED ·Phase: NA
-
Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment
NCT00929357 ·Status: COMPLETED
-
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
NCT01692899 ·Status: COMPLETED
-
Reduced Ultrasound Counts in Rheumatoid Arthritis
NCT02389283 ·Status: UNKNOWN